Selected:

Buy BAY 38-7271 drugs online

520,00$8 100,00$

Buy BAY 38-7271 drugs online

520,00$8 100,00$

BAY 38-7271 Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.

100g
1kg
3kg
500g
50g
Clear
My favorite
My favorite
SKU: N/A Category:

Description

38-7271 Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.

It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials.But its development appears has stopped.

CAS: 212188-60-8
Formula: C20H21F3O5S
Purity: 99,7% min
Molecular weight: 311.461
Appearance: Need to clarify

BAY 38-7271 Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotectiveeffects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.

It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials.But its development appears has stopped.

Additional information

Quantity

, , , ,

Close Menu
×
×

Basket